Bortezomib in relapsed or refractory myeloma patients

被引：0
|
作者：
Leonetti Crescenzi, S. [1 ]
Piccioni, A. L. [1 ]
Bagnato, A. [1 ]
机构：
[1] Osped Sandro Pertini, UOC Ematol, ASL Roma B, Rome, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [31] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    Kumar, S. K.
    LaPlant, B.
    Roy, V.
    Reeder, C. B.
    Lacy, M. Q.
    Gertz, M. A.
    Laumann, K.
    Thompson, M. A.
    Witzig, T. E.
    Buadi, F. K.
    Rivera, C. E.
    Mikhael, J. R.
    Bergsagel, P. L.
    Kapoor, P.
    Hwa, L.
    Fonseca, R.
    Stewart, A. K.
    Chanan-Khan, A.
    Rajkumar, S. V.
    Dispenzieri, A.
    BLOOD CANCER JOURNAL, 2015, 5 : e338 - e338
  • [32] Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma
    Fenk, Roland
    Michael, Mark
    Zohren, Fabian
    Graef, Thorsten
    Czibere, Akos
    Bruns, Ingmar
    Neumann, Frank
    Fenk, Barbara
    Haas, Rainer
    Kobbe, Guido
    LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2345 - 2351
  • [33] Bortezomib in relapsed and refractory multiple myeloma patients.: Experience of a single center
    Calabrese, E.
    Gallucci, C.
    Federico, V
    Mohamad, A.
    Foa, R.
    Petrucci, M. T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 151 - 151
  • [34] Salvage Therapy with Bortezomib and Dexamethasone in Elderly Patients with Relapsed Refractory Multiple Myeloma
    Castelli, Roberto
    Gallipoli, Paolo
    Gidaro, Antonio
    Maddalena, Wu
    Arquati, Massimo
    Deliliers, Giorgio Lambertenghi
    BLOOD, 2015, 126 (23)
  • [35] Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    Gleason, Charise
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Valla, Kelly
    Heffner, Leonard T.
    Bisht, Aditya Singh
    Manubolu, Sanjay
    Watson, Melanie
    Boise, Lawrence H.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
  • [36] Bortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory/relapsed multiple myeloma
    Poenisch, W.
    Bourgeois, M.
    Wang, S. Y.
    Heyn, S.
    Jaekel, N.
    Al Ali, H.
    Niederwieser, D.
    ONKOLOGIE, 2008, 31 : 136 - 136
  • [37] Association of bortezomib, doxorubicin and dexamethasone (PAD) in relapsed and refractory multiple myeloma patients
    Palumbo, A.
    Gay, F.
    Falcone, A.
    Pescosta, N.
    Callea, V
    Caravita, T.
    Morabito, F.
    Falco, P.
    Larocca, A.
    Avonto, I
    Musto, P.
    Cascavilla, N.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 31 - 32
  • [38] The treatment of relapsed and refractory myeloma: Focus on bortezomib and bortezomib-based combinations
    Richardson, P.
    Schlossman, R.
    Ghobrial, I.
    Mitsiades, C.
    Hicleshima, T.
    Chauhan, D.
    Munshi, N.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 21 - 22
  • [39] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Song Mu
    Yoshiaki Kuroda
    Hirohiko Shibayama
    Masayuki Hino
    Takeshi Tajima
    Claudia Corrado
    Rong Lin
    Edward Waldron
    Florence Binlich
    Kenshi Suzuki
    European Journal of Clinical Pharmacology, 2016, 72 : 153 - 161
  • [40] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Mu, Song
    Kuroda, Yoshiaki
    Shibayama, Hirohiko
    Hino, Masayuki
    Tajima, Takeshi
    Corrado, Claudia
    Lin, Rong
    Waldron, Edward
    Binlich, Florence
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 153 - 161
12345